Media stories about Cyclacel Pharmaceuticals (NASDAQ:CYCC) have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cyclacel Pharmaceuticals earned a news sentiment score of 0.11 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 45.9279877728543 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Cyclacel Pharmaceuticals, Inc. (CYCC)- Safe Haven Performance Portfolio Stocks – NASDAQ Times (nasdaqtimes.com)
- Cyclacel Pharma (CYCC) Reports Selection of Recommended … – StreetInsider.com (streetinsider.com)
- Part 2 of study will focus on cyclin E amplified drug resistant solid tumors (globenewswire.com)
- Form 8-K Cyclacel Pharmaceuticals For: Aug 07 (streetinsider.com)
- Healthcare Stock Buy Signal: AxoGen, Inc. (AXGN) ,Cyclacel Pharmaceuticals, Inc. (CYCC) – Street Observer (press release) (streetobserver.com)
Shares of Cyclacel Pharmaceuticals (CYCC) traded down 3.3842% on Tuesday, reaching $1.7101. The company had a trading volume of 389,026 shares. Cyclacel Pharmaceuticals has a 12 month low of $1.56 and a 12 month high of $10.90. The firm’s 50 day moving average is $3.03 and its 200 day moving average is $4.35.
Cyclacel Pharmaceuticals (NASDAQ:CYCC) last announced its quarterly earnings data on Thursday, May 11th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter. Cyclacel Pharmaceuticals had a negative net margin of 1,128.13% and a negative return on equity of 72.48%. On average, equities research analysts predict that Cyclacel Pharmaceuticals will post ($2.25) EPS for the current fiscal year.
Separately, Zacks Investment Research downgraded Cyclacel Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, April 26th.
ILLEGAL ACTIVITY WARNING: This story was first reported by BBNS and is the property of of BBNS. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://baseballnewssource.com/markets/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-cyclacel-pharmaceuticals-cycc-share-price-updated/1308787.html.
In other Cyclacel Pharmaceuticals news, major shareholder Eastern Capital Ltd bought 850,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 19th. The shares were purchased at an average price of $2.00 per share, with a total value of $1,700,000.00. Following the completion of the acquisition, the insider now directly owns 2,167,261 shares of the company’s stock, valued at approximately $4,334,522. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 4.00% of the company’s stock.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors.
Receive News & Ratings for Cyclacel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.